Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Plans Avastin Renal Cell Cancer, Breast Cancer sBLA Filings

Executive Summary

Fueled by positive early data, Genentech is in discussions with FDA regarding a potential sBLA submission for Avastin (bevacizumab) for renal cell cancer, the company announced

You may also be interested in...



Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

Lucentis Faces Additional Pressure From NIH’s Avastin Trials

Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin

UsernamePublicRestriction

Register

PS048568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel